Nilo Therapeutics Raises $101M Series A to Advance Neural-Circuit Therapies

Deal Summary

Nilo Therapeutics launched with a $101M Series A to develop neural-circuit approaches for restoring immune homeostasis. The round was led by The Column Group, DCVC Bio and Lux Capital, with participation from the Gates Foundation and Alexandria Venture Investments; Kim Seth, Ph.D. was named CEO.